BUSINESS
Sai Life Sciences: Differentiated CRDMO business model to help during Trump 2.0
Globally, more than 50 percent of the research and development (R&D) spending is done in nine select pharma hubs, and, hence, it is rewarding to have a presence in these locations.
BUSINESS
Divis Lab: GLP-1 opportunity to unfold in the medium term
Global sales from these drugs in Q3 CY2024 were a staggering $11.2 billion. Street estimates for GLP 1 drugs sales for anti-diabetic and/or obesity control are upwards of $150 billion in 2030.
BUSINESS
Senores IPO: A B2B play in pharma generics
Senores has an interesting business model, focusing on generic product identification and development. For the commercialisation and marketing of those products, it has tied up with large generic players.
BUSINESS
Fed cuts rate but turns hawkish in view of inflation uncertainty
As global trade dynamics are hazy and private capex is fragile, investors should eye bottom-up opportunities in capex recovery and policy supported sectors
BUSINESS
Vijaya Diagnostic Centre: Early success from new geographies reassuring
The company continues to expand beyond its legacy markets — Andhra and Tel-angana — to Pune, Gurugram, and Kolkata
BUSINESS
Sagility: A steady play on US healthcare efficiency initiatives
A defensive bet on the US healthcare spending and upcoming efficiency initiatives
BUSINESS
Sai Life IPO: A pricey proxy for pharma research, development opportunity
More than 50 percent of the global R&D spending is done in nine select pharma hubs, and, hence, it is rewarding to have a presence in these locations
BUSINESS
Should one avoid the FMCG sector now?
The early warning on growth and profit shortfall from Godrej Consumer adds to sectoral concerns
BUSINESS
PI Industries: Quality name wading through industry challenges
Q2 performance below Street expectations and a traction in CDMO is crucial for growth
BUSINESS
Tarsons Products: A ‘pick & shovel’ play in pharma research
The company is set to benefit from the surge in demand seen for plastic labware in the coming days, with US biotech firms decoupling from China being a key factor.
BUSINESS
Suraksha Diagnostics IPO: A play on eastern India healthcare demand
A successful replication of the business model outside the core area will be key to growth
BUSINESS
HUL: Value unlocking on the cards after ice cream business demerger
The high-growth, but low-margin category contributes only 3 percent to HUL’s turnover and needs significant investments.
BUSINESS
Galaxy Surfactants: International business prospects hedge domestic slowdown
Though there was a recovery in rural areas, domestic demand was muted in Q2FY25. US and Europe businesses helped top line growth
BUSINESS
Max Healthcare: Quick turnaround in acquired assets makes us positive on the stock
The company appears well-positioned to gain from sectoral tailwinds, with its focus on expanding presence in key markets, and being a preferred service provider for international patients
BUSINESS
KIMS: A play on hinterland healthcare demand in South India
While the capacity addition pipeline is decent, the growing focus on oncology and transplant centres will strengthen the company’s margin profile.
BUSINESS
Balaji Amines: Methyl amines capacity ramp-up to help in H2 FY25
The company appears to be future-ready with significant investments in higher-margin products without denting its balance sheet
BUSINESS
Fed vs. Trumponomics 2.0: Post rate cut, how should investors position themselves?
Initially, the US central bank will respond primarily to the non-farm payroll trajectory. But later on, any aggressive stance by Trump on global trade, the fiscal deficit and immigration can potentially rekindle inflation
BUSINESS
Sagility IPO: A play on US healthcare outsourcing market
Balance sheet healthy and there is room to raise more funds in future
BUSINESS
Ami Organics: Early CDMO ramp-up aces growth outlook
While the semi-conductor and battery chemical businesses are the new drivers of growth for the long term, it would take time. Near-term growth would be driven by the advanced intermediates business.
BUSINESS
Dabur: A bigger rural footprint, a wider product basket key growth levers
Urban demand has bottomed out and expected to pick up once food inflation stabilises
BUSINESS
Cipla: M&A positioning, new US regime are key wild cards
The management is primarily focusing on Indian assets which can bring synergy, followed by US assets. Cipla’s continued investment in US subsidiary InvaGen would de-risk the business model from a compliance point of view.
BUSINESS
Syngene: FY25 guidance intact as biotech funding revives
The macro tailwinds are strong as biotech firms are looking for a China alternative and the US Biotech Act can potentially decouple China’s biotech supply chain from the US biotech value chain
BUSINESS
Navin Fluorine: Strong order book visibility for CDMO, specialty segments
The capex projects for agro-specialty at Dahej, the additional R-32 capacity, and the anhydrous hydrofluoric acid plants should also contribute to FY26 earnings
BUSINESS
Himadri Speciality: Little comfort on valuation
In the near term, HSCL could continue to benefit from the demand-supply mismatch in Europe. HSCL’s long-term plan is to diversify into new-age businesses. This can have a long gestation period and face technological challenges
